Windlas Biotech Reports Record Q1 FY27 Revenue of ₹248 Cr
Windlas Biotech Ltd announced its unaudited financial results for Q1 FY27, marking the 14th consecutive quarter of record revenue, which stood at ₹248 crores, an 18% year-on-year growth. Adjusted EBITDA grew 26% YoY to ₹34 crores, and Adjusted PAT increased by 37% YoY to ₹25 crores. The company also successfully completed a ₹47 crore share buyback without promoter participation and declared a dividend of ₹13 crores for FY26. The Generic Formulations CDMO vertical was the primary revenue driver, contributing 84% to consolidated revenue with a 29% YoY growth. The Trade Generics & Institutional vertical saw a 32% YoY decline, while the Exports vertical grew by 79% YoY. The company is on track for the commercialization of Plant-6 in H1 FY27.
Key Highlights
- 14th consecutive quarter of record revenue at ₹248 crores (18% YoY growth).
- Adjusted EBITDA up 26% YoY to ₹34 crores; Adjusted PAT up 37% YoY to ₹25 crores.
- Completed ₹47 crore share buyback without promoter participation.
- Generic Formulations CDMO vertical revenue grew 29% YoY, contributing 84% of total revenue.
- EPS improved to ₹8.46 for Q1 FY27.
Price Impact
More from WINDLAS*